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Abstract
Ischemic heart disease is a major cause of death and disabili-
ties worldwide. Unfortunately, not all patients are suitable for 
direct revascularization. Cell-based therapies may be alterna-
tive options because of their potential to promote neovascu-
larisation and endothelial repair, improving myocardial perfu-
sion. The success of cell-based therapies depends on the type 
of implanted stem cells, delivery method and underlying dis-
ease. Several different cell populations including bone marrow-
derived mononuclear cells (MNCs), mesenchymal stromal cells 
(MSCs), CD34+, CD133+, endothelial progenitor cells, adipose-
derived mesenchymal stromal cells (ASCs) and stem cells from 
placenta and umbilical cord have been investigated. Presently, 
no consensus exists about the best cell type for clinical regen-
erative therapy. Because the system of coronary arteries in the 
ischemic area is poor and most of the coronary artery is sig-
nificantly narrowed or closed, direct implantation of stem cells 
in the ischemic area of the heart muscle appears an attractive 
method. 
Key words: ischemic heart disease, stem cells, regenerative 
medicine.
Streszczenie
Choroba niedokrwienna serca jest główną przyczyną zgonu 
i niepełnosprawności na świecie. Nie wszyscy pacjenci mogą 
jednak być zakwalifikowani do bezpośrednich metod rewa-
skularyzacji. Alternatywą są terapie oparte na wykorzystaniu 
komórek macierzystych ze względu na ich potencjał do odbu-
dowy łożyska naczyniowego oraz poprawy perfuzji mięśnia 
sercowego. Sukces terapii z użyciem komórek macierzystych 
zależy od rodzaju wszczepionych komórek macierzystych, 
metody podawania oraz choroby podstawowej. Przebadano 
kilka różnych populacji komórek, np. jednojądrzaste komór-
ki szpiku kostnego (MNC), mezenchymalne komórki zrębowe 
(MSC), CD34+, CD133+, śródbłonkowe komórki progenitoro-
we, mezenchymalne komórki zrębowe pochodzące z tkanki 
tłuszczowej (ASC) i komórki macierzyste z łożyska, pępowiny 
oraz serce. Obecnie nie ma konsensusu dotyczącego wyboru 
optymalnego typu komórek w klinicznej terapii regeneracyj-
nej mięśnia sercowego. Ponieważ układ tętnic wieńcowych 
w obszarze niedokrwienia jest słaby, a większość tętnic wień-
cowych jest znacznie zwężona lub zamknięta, bezpośrednia 
implantacja komórek macierzystych w obszarze niedokrwienia 
mięśnia sercowego wydaje się atrakcyjną metodą.
Słowa kluczowe: choroba niedokrwienna serca, komórki ma-
cierzyste, medycyna regeneracyjna.
Address for correspondence: Radoslaw Litwinowicz MD, PhD, Department of Cardiovascular Surgery and Transplantology,  
Jagiellonian University, John Paul II Hospital, 80 Pradnicka St, 31-202 Krakow, Poland, phone: +48 12 614 32 03, fax: +48 12 614 25 25,  
e-mail: radek.litwinowicz@gmail.com  
Received: 10.06.2018, accepted: 12.06.2018.
The use of stem cells in ischemic heart disease treatment
Radoslaw Litwinowicz, Bogusław Kapelak, Jerzy Sadowski, Anna Kędziora, Krzysztof Bartus
Department of Cardiovascular Surgery and Transplantology, Jagiellonian University Medical College,  
John Paul II Hospital, Krakow, Poland 
Kardiochirurgia i Torakochirurgia Polska 2018; 15 (3): 196-199
Introduction
In the U.S. alone 28.1 million people are living with car-
diovascular disease, and this number increases every year 
[1]. Coronary artery disease (CAD) is a major cause of death 
and disability in developed countries, including in the young 
adult population [2]. The gold standard for treatment pa-
tients with ischemic heart disease is percutaneous coronary 
intervention (PCI) or coronary artery bypass grafting (CABG) 
[3–5]. Nevertheless, an increasing number of patients with 
advanced coronary artery disease become suboptimal can-
didates for further revascularization, and continue to have 
symptoms despite the best medical management [6].
Regenerative therapies using stem cells for the repair 
of heart tissue have been widely used in preclinical and 
clinical studies during the past 16 years [7]. Induction of an-
giogenesis to create de novo collateral vessels within an 
area of compromised blood flow has been in development 
since the mid-1980s, soon after the first in vivo reports on 
the angiogenic effect of recombinant fibroblast growth fac-
tor (FGF) [8].
There are several factors that significantly affect the ef-
fectiveness of stem cell therapy. Optimal delivery technique 
is crucial for the precise delivery of stem cells to a specific 
area of the myocardium, settlement and differentiation. 
Among the different approaches, direct implantation of 
cells into heart tissue still attracts the most clinical atten-
tion. In this review, we will focus on the intramyocardial de-
livery of stem cells in treatment of ischemic heart disease.
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 Delivery methods
The first documented attempt at internal local drug de-
livery was made by Folkman et al. in 1964 [9]. These inves-
tigators attempted to treat surgically induced heart block 
in dogs through intramyocardial (IMC) release of digitoxin, 
isoproterenol, tyrosine, thyroid I125, and ethylenediamine-
tetraacetic acid embedded in a silicone rubber cylindrical 
capsule (5 mm × 15 mm) surgically implanted in the myo-
cardial wall near the apex. 
A range of technologies have been used to deploy the 
intramyocardial delivery route, from direct syringe injection 
to the left ventricle under visual control to minimally inva-
sive delivery using guided percutaneous transendocardial 
injection to the ischemic area of the left ventricle guided by 
the NOGA system. 
It was found that direct injection into the myocardium 
immediately after the LAD occlusion provided the largest 
stem cell retention in the injured myocardium (14 ±4% of 
the total injected cells) [10]. Direct surgical myocardial in-
jection can be performed in hypokinetic myocardial areas 
not suitable for coronary artery bypass grafting (CABG) [11].
Many investigators have explored intracoronary (IC) de-
livery of therapeutic agents. while this approach preferen-
tially targets myocardial tissue, it usually does not provide 
significant drug retention in heart muscle.
Penicka et al. [12] demonstrated that approximately 5% 
and 1% of the stem cells remain in the human myocardium 
2 h and 18 h post-intracoronary application, respectively, 
while the vast majority of the cells can be found in the 
spleen, liver, lung, lymph nodes and BM already a couple of 
hours after transplantation. 
Intramyocardial cellular delivery cell therapy provid-
ed a benefit in increasing 6-min walk distance (95% CI: 
21.09–142.62 m, p = 0.008), improving the Minnesota Liv-
ing with Heart Failure (MLHF) score (95% CI: –25.21 to –3.55, 
p = 0.009), and lowering the incidence of NYHA functional 
class deterioration (95% CI: 0.05–0.76, p = 0.02). Meanwhile, 
cell therapy did not significantly increase the incidence of 
acute heart failure during the cell injection procedure (RR 
= 1.68, 95% CI: 0.43–6.63, p = 0.46; I2 = 0%) or the risk of 
ventricular tachycardia during follow-up (RR = 1.56, 95% CI: 
0.73–3.32, p = 0.25; I2 = 0%) [13].
Intramyocardial delivery has been implemented via 
minimally invasive transcutaneous left heart catheteriza-
tion for transendocardial injection [14] and direct transepi-
cardial injections under direct visualization during sternot-
omy [15] or left small thoracotomy [16]. Minimally invasive 
access to the heart muscle is a safe procedure, widely used 
in cardiac surgery [17]. However, without the use of extra-
corporeal circulation, it allows only for safe access to the 
anterior and anterolateral wall of the heart, which may be 
a limitation of this approach. Full sternotomy meanwhile 
is associated with the risk of perioperative complications 
such as bleeding, infections, abnormal sternal healing or 
respiratory complications [18, 19].
Recently published research on animals revealed that 
intracoronary stem cell delivery decreased absolute myo-
cardial blood flow, with a consequent increase in myocardi-
al expression of the oxidative stress marker matrix metallo-
proteinase-2 and reduced CXCR4 receptor expression with 
a lower level of myocardial homing and angiogenic factor 
release as compared to intramyocardial cell delivery [20]. 
It should be emphasized that patient safety must always 
be taken into account in the planning of clinical trials. This is 
especially true given the adverse events reported in the Athe-
na trials [21]. eighteen of 31 (58.1%) patients were reported 
to have at least one serious adverse event during the trial 
(ADSC 9/17 (52.9%), placebo 9/14 (64.3%)). The reasons for 
such high adverse event rates in the Athena trials are unclear 
but could be dependent on cell delivery techniques used.
The limitations of intramyocardial delivery include the 
relatively small volume of drug delivery vehicle, the poten-
tial danger of disrupting myocardium, and the iatrogenic 
damage to coronary vessels or His-Purkinje fibers.
Types of stem cells
Many types of stem cells are used in scientific research, 
since the first-in-man application in 2001 and several prom-
ising clinical pilot trials [22]. Cell-based therapy promotes 
tissue regeneration through direct tissue transdifferentia-
tion, paracrine signaling and promotion of neoangiogen-
esis. Mechanisms responsible for neoangiogenesis involve 
release of paracrine factors such as vascular endothelial 
growth factor (VEGF), basic fibroblast growth factor (bFGF), 
angiopoietin-1 and many others. 
Bone marrow-derived mononuclear cells (BM-MNCs) 
represent a heterogeneous population: hematopoietic 
stem cells, mesenchymal stem cells (MSCs) and endothelial 
progenitor cells (ePCs). It is generally accepted that MSCs 
can express CD44, CD29, CD73, CD90 and CD105, as well 
as CD106, CD166, and ICAM-1, but not the hematopoietic 
markers CD45, CD34, CD14, CD79a, CD11b and HLA-DR [23]. 
Many murine, rat, and swine studies have demonstrated 
that IMC injections of bone mesenchymal stem cells (BMSCs) 
into the ischemic and infarcted myocardium induce angio-
genesis and myocardial blood perfusion, and improve car-
diac function [24, 25].
In the COMPARe CPM-RMI trial, wherein bone marrow-
derived mononuclear cells (MNCs) and CD133+ stem cells 
were implanted, increased left ventricular ejection frac-
tion by 9% (95% confidence intervals (CI): 2.14–15.78%, 
p = 0.01) and improved decreased systolic wall thickening 
by –3.7 (95% CI: –7.07 to –0.42, p = 0.03) were found in 
both cell type groups [26]. Patients from all study groups 
received the injections at the end of the cardiopulmonary 
bypass and cold blood cardioplegic arrest, and just prior to 
removal of the aortic cross clamp. 
In patients with left ventricle dysfunction, intramyo-
cardial injection of autologous bone marrow mononuclear 
cells improve regional wall thickening (6.6 ±6.3% vs. 11.7 
±7.0% at 3 months, p < 0.01) and perfusion score (3.5 ±0.7 
vs. 3.0 ±0.9 at 3 months, p = 0.02), with a trend toward an 
improved fluorine-18 fluorodeoxyglucose score (2.9 ±0.9 vs. 
2.6 ±1.0 at 3 months, p = 0.06) [27].
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Also in the long-term follow-up period, clinical status 
improvement, no new regional wall motion abnormali-
ties and increase of global ejection fraction were observed 
[28, 29].
In conclusion, many clinical trials have demonstrated 
safety and efficiency of intramyocardial stem cell injections 
into patients with acute and chronic myocardial infarction, 
as well as improvement in myocardial perfusion and func-
tion [28, 30, 31].
Adipose tissue is one of the most highly vascularized 
tissues in the body. Adipose tissue-derived stem cells 
(ADSCs) are a cell population with characteristics that are 
very similar, but not identical, to those of BMSCs [32, 33]. 
In animal studies, intramyocardially injected adipose-
derived stromal cells have demonstrated increased LveF, 
wall thickness, and reduction of infarct size in rats [34].
Results from a randomized placebo-controlled study 
(MyStromalCell Trial) revealed that bicycle exercise tol-
erance increased significantly by the time of 22 s (95% 
CI: –164 to 208 s, p = 0.034), 4 watts (95% CI: – 33 to 41, 
p = 0.048), and 0.2 MeTs (95% CI: –1.4 to 1.8, p = 0.048) 
in the adipose-derived stromal cell group while there was 
a non-significant increase in the placebo group by time of 
9 s (95% CI: –203 to 221 s, p = 0.053), 7 watts (95% CI: –40 
to 54, p = 0.41), and 0.1 MeTs (95% CI: –1.7 to 1.9, p = 0.757) 
at 6 months follow-up [35].
The Athena trials used an intramyocardial injection of 
adipose-derived stromal vascular fraction (SvF) cells in pa-
tients with ischemic heart failure and showed that maxi-
mum oxygen consumption on exercise treadmill testing 
was increased in the therapy group but not significantly 
different from the placebo group [21]. Used SVF cell popula-
tions are however heterogeneous, compromising approxi-
mately 2% ASCs [36].
Schenke-Layland et al. reported that compared with the 
control group, the ADSCs-treated group showed less dilated 
left ventricular end-diastolic dimension, and significantly 
improved ejection fraction and cardiac output after MI [37].
Currently, several studies using adipose derived stem 
cells are in progress. A multicentre, double-blind, placebo-
controlled phase II study is designed to demonstrate safety 
and the regenerative efficacy of direct intramyocardial in-
jections of allogeneic adipose-derived stromal cells in pa-
tients with chronic ischemic heart failure [38]. 
Konstanty-Kalandyk et al. reported the safety and fea-
sibility of delivery of fresh ADSCs intramyocardially, using 
a medical laser, to patients with chronic ischemic heart 
disease who did not qualify for standard methods of treat-
ment (percutaneous coronary intervention, coronary artery 
bypass grafting) [16].
Conclusions
Intramyocardial delivery of stem cells is more compli-
cated than intracoronary administration, but it is safe and 
may provide better therapeutic outcomes. Further studies 
should be designed to define the optimal cell type to treat 
ischemic heart disease, including combination cell therapy.
Many authors emphasize the importance of proper se-
lection of patients for clinical study using stem cells. Prob-
ably some of the patients treated with stem cells respond 
poorly or not at all to the given stem cells. It may be related 
to the patient’s age, accompanying diseases, medications 
or individual predispositions of the patients.
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